Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 18/20 | 0.69 |
| ▸ | PTGS1 | P23219 | 12/20 | 0.69 |
| ▸ | PGR | P06401 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7681706 | 0.95 | PTGS2 (0.63) | PTGS2PTGS1PGR | |
| SCHEMBL7002074 | 0.90 | PTGS2 (0.59) | PTGS2PTGS1 | |
| Polmacoxib SCHEMBL29351757 | 0.89 | PTGS2 (0.55) | PTGS2PTGS1PGR | |
| Polmacoxib SCHEMBL3233093 | 0.89 | PTGS2 (0.55) | PTGS2PTGS1PGR | |
| SCHEMBL6995425 | 0.89 | PTGS2 (0.59) | PTGS2PTGS1 | |
| SCHEMBL6994742 | 0.88 | PTGS2 (0.53) | PTGS2PTGS1 | |
| SCHEMBL6991495 | 0.87 | PTGS2 (0.53) | PTGS2PTGS1PGR | |
| SCHEMBL6997951 | 0.87 | PTGS2 (0.64) | PTGS2PTGS1PGR | |
| SCHEMBL7000001 | 0.86 | PTGS2 (0.51) | PTGS2PTGS1 | |
| SCHEMBL6997585 | 0.86 | PTGS2 (0.57) | PTGS2PTGS1PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1109799-B1 | 4,5-DIARYL-3(2H)-FURANONE DERIVATIVES AS CYCLOOXYGENASE-2 INHIBITORS | PACIFIC CORP (KR) | 2003-12-17 | — | — | EP | claimed |
| JP-2003513917-A | — | — | 2003-04-15 | — | — | JP | claimed |
| US-6492416-B1 | TREATING INFLAMMATION AND ASSOCIATED DISORDERS | PACIFIC CORPORATION (KR) | 2002-12-10 | — | — | US | claimed |
| EP-1242063-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF NEUROLOGICAL DISORDERS AND NEURODEGENERATIVE DISEASES | Massachusetts Institute of Technology Inc. (US) | 2002-09-25 | — | — | EP | claimed |
| EP-1109799-A1 | 4,5-DIARYL-3(2H)-FURANONE DERIVATIVES AS CYCLOOXYGENASE-2 INHIBITORS | PACIFIC CORPORATION (KR) | 2001-06-27 | — | — | EP | claimed |
| WO-2001034138-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF NEUROLOGICAL DISORDERS AND NEURODEGENERATIVE DISEASES | MASSACHUSETTS INSTITUTE OF TECHNOLOGY, INC. (US) | 2001-05-17 | — | — | WO | claimed |
| WO-2000061571-A1 | 4,5-DIARYL-3(2H)-FURANONE DERIVATIVES AS CYCLOOXYGENASE-2 INHIBITORS | PACIFIC CORPORATION (KR) | 2000-10-19 | — | — | WO | claimed |
| US-20230256104-A1 | CANNABINOID CONJUGATE MOLECULES | AKOS BIOSCIENCES, INC. | 2023-08-17 | — | — | US | disclosed |
| US-20230256103-A1 | CANNABINOID CONJUGATE MOLECULES | AKOS BIOSCIENCES INC. | 2023-08-17 | — | — | US | disclosed |
| US-11660348-B1 | Cannabinoid conjugate molecules | AKOS BIOSCIENCES, INC. (US) | 2023-05-30 | — | — | US | disclosed |
| CN-1166658-C | 4,5 diaryl-3 (2H) -furanone derivatives as cyclooxygenase-2 inhibitors | ��ʽ����̫ƽ�� | 2004-09-15 | — | — | CN | disclosed |
| EP-1109799-B1 | 4,5-DIARYL-3(2H)-FURANONE DERIVATIVES AS CYCLOOXYGENASE-2 INHIBITORS | PACIFIC CORP (KR) | 2003-12-17 | — | — | EP | disclosed |
| US-6492416-B1 | TREATING INFLAMMATION AND ASSOCIATED DISORDERS | PACIFIC CORPORATION (KR) | 2002-12-10 | — | — | US | disclosed |
| CN-1348447-A | 4,5 diaryl-3 (2H) -furanone derivatives as cyclooxygenase-2 inhibitors | PACIFIC CORP (KR) | 2002-05-08 | — | — | CN | disclosed |
| EP-1109799-A1 | 4,5-DIARYL-3(2H)-FURANONE DERIVATIVES AS CYCLOOXYGENASE-2 INHIBITORS | PACIFIC CORPORATION (KR) | 2001-06-27 | — | — | EP | disclosed |
| WO-2000061571-A1 | 4,5-DIARYL-3(2H)-FURANONE DERIVATIVES AS CYCLOOXYGENASE-2 INHIBITORS | PACIFIC CORPORATION (KR) | 2000-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230256104-A1 | CANNABINOID CONJUGATE MOLECULES | CNR2, CNR1, FAAH2 | PTGS2 9/4885PTGS1 33/4885PGR 1639/4885 |
| US-20230256103-A1 | CANNABINOID CONJUGATE MOLECULES | CNR2, CNR1, FAAH2 | PTGS2 9/4885PTGS1 33/4885PGR 1639/4885 |
| US-11660348-B1 | Cannabinoid conjugate molecules | CNR2, CNR1, FAAH2 | PTGS2 9/4885PTGS1 33/4885PGR 1639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.